Thursday, January 18, 2018 -- Robot scientist Eve helps University of Cambridge researchers in breakthrough discovery that puts bathroom staple into fight against killer disease.
Tuesday, January 16, 2018 -- Chris Dall | News Reporter | CIDRAP NewsJan 16, 2018Researchers identify more than 80 genes that contribute to resistance.
Friday, January 12, 2018 -- The malaria parasite’s shifting defenses against antimalarial drugs have been shadowed by scientists on the lookout for new druggable targets. The scientists, led by researchers based at the University of California San Diego School of Medicine, used experimental evolution and whole-genome analysis to identify drug-resistance genes. The scientists conducted this work systematically, producing a map of the chemogenetic landscape that could guide the design of small-molecule inhibitors against the malaria parasite, which kills hundreds of thousands of people each year. Details of the work appeared January 12 in the journal Science, in an article entitled “Mapping the Malaria Parasite Druggable Genome by Using In Vitro Evolution and Chemogenomics.” This article describes how the scientists performed a genome analysis
Thursday, January 11, 2018 -- Chemogenetic characterization through in vitro evolution combined with whole-genome analysis can identify antimalarial drug targets and drug-resistance genes. We performed a genome analysis of 262 Plasmodium falciparum parasites resistant to 37 diverse compounds. We found 159 gene amplifications and 148 nonsynonymous changes in 83 genes associated with drug-resistance acquisition, where gene amplifications contributed to one-third of resistance acquisition events. Beyond confirming previously identified multidrug-resistance mechanisms, we discovered hitherto unrecognized drug target–inhibitor pairs, including thymidylate synthase and a benzoquinazolinone, farnesyltransferase and a pyrimidinedione, and a dipeptidylpeptidase and an arylurea. This exploration of the P. falciparum resistome and druggable genome will likely guide drug discovery and structural biology efforts, while also advancing our understanding of resistance mechanisms available to the malaria parasite.
Thursday, January 11, 2018 -- Malaria remains a complicated global health problem that is on the precipice of a resurgence in areas where it has long since subsided if climate change continues its “heated” rise. Understanding the molecular mechanisms that allow this pervasive parasite to traverse multiple hosts could hold the key to disease elimination, or, at the very least, keeping outbreaks under control. Now, investigators at Penn State University (PSU) have uncovered that malaria parasites have not one, but two, specialized proteins that protect its messenger RNAs (mRNAs) until the parasite takes up residence in a new mosquito or a human host. Findings from the new study were published recently in mSphere in an article entitled “ Nuclear, Cytosolic, and Surface-Localized Poly(A)-Binding Proteins
Friday, January 05, 2018 -- NewsIn December, the company submitted a New Drug Application (NDA) to the FDA for the use of Tafenoquine to prevent malaria in adults traveling to areas where the disease is prevalent.Contributed Author: 60 Degrees PharmaceuticalsTopics: Drug Development
Thursday, December 28, 2017 -- (Natural News) Most conversations involving drones revolve around the fact that they can be used for surveillance on individuals, and so they should be thought of as potentially scary pieces of technology. But a community in East Africa has figured out a way to put the novel new technology to good use in their continuing... Read More
Wednesday, December 27, 2017 -- by Puthupparampil V. Scaria, Beth Chen, Christopher G. Rowe, David S. Jones, Emma Barnafo, Elizabeth R. Fischer, Charles Anderson, Nicholas J. MacDonald, Lynn Lambert, Kelly M. Rausch, David L. Narum, Patrick E. Duffy Chemical conjugation of polysaccharide to carrier proteins has been a successful strategy to generate potent vaccines against bacterial pathogens. We developed a similar approach for poorly immunogenic malaria protein antigens. Our lead candidates in clinical trials are the malaria transmission blocking vaccine antigens, Pfs25 and Pfs230D1, individually conjugated to the carrier protein Exoprotein A (EPA) through thioether chemistry. These conjugates form nanoparticles that show enhanced immunogenicity compared to unconjugated antigens. In this study, we examined the broad applicability of this technology as a vaccine development platform,
Tuesday, December 19, 2017 -- Earlier this month, pharmaceutical manufacturer, Eli Lilly announced that it will no longer be producing IV quinidine gluconate, but plans to continue distributing the product until the current stock expires (March 2019). As of today, intravenous quinidine gluconate remains available for the treatment of severe malaria. CDC and FDA are developing a strategy to ensure continued […] The post Malaria treatment: Eli Lilly announces discontinuation of IV quinidine appeared first on Outbreak News Today.
Monday, December 18, 2017 -- Researchers have discovered a ‘molecular handshake’ that allows malaria parasites to escape from the host’s immune system.
Friday, December 15, 2017 -- BO RAI, Thailand (Reuters) - Once a smuggling stop for Cambodia's Khmer Rouge guerrillas, Thailand's border town of Bo Rai finds itself on the frontline of a new battle against drug-resistant strains of malaria that could frustrate global attempts to stamp out the disease.
Friday, December 15, 2017 -- Indiana University School of Medicine researchers have identified a way to block the ability of parasites that cause malaria to shield themselves against drug treatments in infected mice--a finding that could lead to the development of new approaches to combat this deadly disease in humans.
Thursday, December 14, 2017 -- (Natural News) Though it might seem like a rare, foreign disease to many Americans, nearly half of the entire world’s population is at risk of contracting malaria, a serious and sometimes fatal parasitic disease spread by Anopheles mosquitoes. Symptoms vary, and can include less acute conditions like fever, nausea, vomiting and general weakness, or serious,... Read More
Tuesday, December 12, 2017 -- Investigators evaluated long-term outcomes with antimalarial use and organ damage, flares, disease activity, glucocorticoid use, and antimalarial associated retinopathy.
Friday, December 08, 2017 -- Global efforts to eradicate malaria are crucially dependent on scientists' ability to outsmart the malaria parasite. And Plasmodium falciparum is notoriously clever: It is quick to develop resistance against medications and has such a complex life cycle that blocking it effectively with a vaccine has thus far proved elusive.
Tuesday, December 05, 2017 -- Scientists have identified a protein involved in the life cycle of the malarial parasite, paving the way for a new vaccine to reduce disease spread.
Monday, December 04, 2017 -- Malaria is one of three major infectious diseases affecting approximately 300 million people every year, accounting for about 500,000 deaths, but effective vaccine development has not been successful.
Friday, December 01, 2017 -- by Samson S. Kiware, Nakul Chitnis, Allison Tatarsky, Sean Wu, Héctor Manuel Sánchez Castellanos, Roly Gosling, David Smith, John M. Marshall Background Despite great achievements by insecticide-treated nets (ITNs) and indoor residual spraying (IRS) in reducing malaria transmission, it is unlikely these tools will be sufficient to eliminate malaria transmission on their own in many settings today. Fortunately, field experiments indicate that there are many promising vector control interventions that can be used to complement ITNs and/or IRS by targeting a wide range of biological and environmental mosquito resources. The majority of these experiments were performed to test a single vector control intervention in isolation; however, there is growing evidence and consensus that effective vector control with the goal
Friday, December 01, 2017 -- Switching from 1 antimalarial agent to a second may be beneficial in patients with cutaneous lupus erythematosus.
Thursday, November 30, 2017 -- GlaxoSmithKline and the Medicines for Malaria Venture are seeking permission to market single-dose tafenoquine in the US to prevent relapse of Plasmodium vivax malaria.